SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: BMcV who wrote (1316)10/23/1998 9:13:00 PM
From: John Metcalf  Read Replies (1) of 10280
 
In this case (losing $1.05 per share in Q3) I regard the price decline as positive. The company has made absolutely huge advances on a multiplicity of programs (and that's where the money went). They have a Levalbuterol sales force now, and ICE Prozac is going to clinicals, and they have a Propulsid deal, and S-Oxybutinin is near trial results, like Norastemizole, and and and.... The company is brazenly talking about a CNS franchise to go with the respiratory franchise.

Some weak hands are being shaken loose, or are taking profits. This is a great deal for me as a long-term holder looking for more stock or cheaper calls. Sell, sell, sell!
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News